Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TrasGEX
- Development stage
- Phase 1
- Lead developer
- Pentixapharm
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TrasGEX is a second-generation, glyco-optimized monoclonal antibody derived from trastuzumab. It is engineered to enhance antibody-dependent cellular cytotoxicity (ADCC) while fully retaining the antigen-binding properties of trastuzumab to human epidermal growth factor receptor 2 (HER2). The optimization involves modification of N-glycans with low fucose content, resulting in higher binding affinity to FcγRIIIa on natural killer cells and improved ADCC activity compared to conventional trastuzumab. TrasGEX has demonstrated antitumor activity in patients with advanced HER2-positive carcinomas and may benefit a broader patient population due to its enhanced efficacy across different FcγRIIIa allotypes. The drug was developed using the GlycoExpress platform by Glycotope and has been evaluated in phase I clinical trials for safety, pharmacokinetics, and preliminary efficacy[1][3][5][6][7].
- Other names
- glycooptimized trastuzumab-gexglycoengineered trastuzumab-gex
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TrasGEX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TrasGEX.